Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat
Status:
Suspended
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and
well-tolerated as a combination therapy and to show clinically beneficial for COVID-19
patients.